AGP Executive Report
Last update: 6 hours agoMedicare GLP-1 price relief: CMS says its Medicare GLP-1 Bridge program will launch July 1 and run through end of 2027, aiming to lower costs for some weight-loss drugs while bridging into a broader lifestyle-and-medication model. FDA hypertension breakthrough: AstraZeneca’s Baxfendy, the first FDA-approved drug that targets aldosterone production, was approved for adults with persistently uncontrolled high blood pressure—clinicians call it a “new way” to treat a root cause. New dementia detection funding: London-based Prema Cognition closed an oversubscribed £550,000 round to expand clinical data for PREMAZ, a memory test designed to spot subtle cognitive changes years earlier. Health info skepticism: A Pew survey finds about 4 in 10 U.S. adults get health info from social media or podcasts, but only ~4 in 10 influencers list health-professional credentials—experts urge vetting before acting. Sleep care partnerships: ResMed and ŌURA teamed up to expand sleep education and pathways to care, including links for people with signs of sleep apnea.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
